Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease Taguchi H; Planque S; Nishiyama Y; Szabo P; Weksler ME; Friedland RP; Paul SAutoimmun Rev 2008[May]; 7 (5): 391-7Immunoglobulins (Igs) that bind amyloid beta peptide (Abeta) are under clinical trials for immunotherapy of Alzheimer disease (AD). We have identified IgMs and recombinant Ig fragments that hydrolyze Abeta. Hydrolysis of peripheral Abeta by the IgMs may induce increased Abeta release from the brain. The catalytic IgMs are increased in AD patients, presumably reflecting a protective autoimmune response. Reduced Abeta aggregation and neurotoxicity attributable to the catalytic function were evident. These findings provide a foundation for development of catalytic Igs for AD immunotherapy.|Alzheimer Disease/*immunology/metabolism/therapy[MESH]|Amyloid beta-Peptides/immunology/*metabolism[MESH]|Antibodies, Catalytic/immunology/*metabolism/therapeutic use[MESH]|Antibodies, Monoclonal/immunology[MESH]|Autoantibodies/immunology/*metabolism[MESH]|Humans[MESH]|Hydrolysis[MESH]|Immunoglobulin M/immunology/*metabolism[MESH]|Immunotherapy[MESH] |